Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiac troponin elevation and mortality in takotsubo syndrome: New insights from the international takotsubo registry.

European journal of clinical investigation·2024

Same author

Cellular and extracellular proteomic profiling of paradoxical low-flow low-gradient aortic stenosis myocardium.

Frontiers in cardiovascular medicine·2024

Same author

Diabetes mellitus is associated with low exercise capacity and impaired peripheral vasodilation in patients with heart failure - a propensity score-matched study.

Diabetes research and clinical practice·2024

Same author

Temporal Trends in Takotsubo Syndrome: Results From the International Takotsubo Registry.

Journal of the American College of Cardiology·2024

Same author

Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2.

Journal of the American College of Cardiology·2024

Same author

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.

The New England journal of medicine·2024

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Cardiac inotropes: current agents and future directions.

Gerd Hasenfuss¹, John R Teerlink

¹Department of Cardiology and Pneumology, University Medical Center, Heart Research Center Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany. hasenfus@med.uni-goettingen.de

European Heart Journal

|March 11, 2011

Summary

This summary is machine-generated.

Novel therapies are emerging to improve heart function, addressing limitations of current drugs for heart failure. These approaches target mechanisms like calcium handling and cardiac myosin, offering hope for better treatments.

More Related Videos

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Related Experiment Videos

Last Updated: Jun 3, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Area of Science:

Cardiovascular Science
Pharmacology
Biotechnology

Background:

Intrinsic cardiac inotropic stimulation is crucial for cardiovascular regulation.
Current inotropic drugs offer limited long-term benefits for heart failure patients.
There is an unmet clinical need for safe and effective cardiac performance enhancers.

Purpose of the Study:

To review novel therapeutic strategies for improving cardiac function.
To highlight emerging agents targeting new mechanisms in heart failure.
To discuss the potential of these novel approaches in clinical practice.

Main Methods:

Review of experimental and early clinical studies on novel inotropic agents.
Analysis of mechanisms including sodium-potassium-ATPase inhibition, SERCA stimulation, cardiac myosin activation, gene therapy, nitroxyl donation, ryanodine receptor stabilization, and metabolic modulation.
Evaluation of lusitropic, inotropic, and vasodilatory effects.

Main Results:

Istaroxime shows inotropic and lusitropic properties by inhibiting Na+/K+-ATPase and stimulating SERCA.
Cardiac myosin activators improve cardiac performance by direct acto-myosin cross-bridge activation.
Gene therapy for SERCA2a, nitroxyl donors, ryanodine receptor stabilizers, and metabolic modulators show promise in pre-clinical and early studies.

Conclusions:

Novel therapeutic agents targeting diverse mechanisms offer promising new options for heart failure.
These approaches aim to improve cardiac performance with a favorable safety profile.
Emerging strategies provide hope for more effective treatments for cardiovascular conditions.